Presentation_1_No Evidence for a Decrease in Physical Activity Among Swiss Office Workers During COVID-19: A Longitudinal Study.pdf by Andrea Martina Aegerter (10127111)

“…Weak statistical evidence for a decline in total physical activity in metabolic equivalent of task minutes per week (MET min/week) was found (estimate = −292, 95% CI from – ∞ to 74, p-value = 0.09), with no evidence for a decrease in the three types of activity: walking (estimate = −189, 95% CI from – ∞ to 100, p-value = 0.28), moderate-intensity activity (estimate = −200, 95% CI from – ∞ to 30, p-value = 0.22) and vigorous-intensity activity (estimate = 80, 95% CI from – ∞ to 460, p-value = 0.74). …”

Decreased expression of TCA cycle and ETC enzymes in kidneys from rats administered Tl. by Sho Sugahara (11895828)

Preoperative and postoperative questionnaire scores of groups A, B, C, D, E, F, and G. by Régis Cohen (11419436)

Subjects:

TG6-44 treatment decreases IFN-β levels in A/X31-infected THP-1 cells. by Juan A. De La Cruz (11154187)

TG6-44 treatment leads to decrease in A/X31-induced cell death in THP-1 cells. by Juan A. De La Cruz (11154187)

Cytochalasin D decreases pyroptosis in TLR ligand-activated Raw264.7 cells. by Peeraya Ekchariyawat (3911113)

<i>neurod1</i>^<i>ΔUCE</i> homozygous mutants display a decrease in the expression of several EE hormones. by Anne Sophie Reuter (12239993)

Incorporating a social responsibility goal in the prompt causes overleverage in utilities (A) and decreases risk of low ESG rating (B) (Study 3). by Philipp Winder (21615570)

CcnA mutation of Loop A decreases the interaction with the 5′ UTR of P2-<i>ctrA</i> mRNA and 5′ UTR of <i>gcrA</i> mRNA. by Wanassa Beroual (5314028)

Study Flow Diagram. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to Lufotrelvir vs placebo day 1–90. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses after treatment with nMAb vs placebo, day 1-90 (pooled nMAb treatments). by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to Ensovibep vs placebo day 1–90. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Sotrovimab. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Amubarvimab/ Romlusevimab. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Tixagevimab/ Cilgavimab. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Bamlanivimab. by Elizabeth S. Munroe (21568166)

Subjects:

Longitudinal antibody and antigen responses to treatment vs placebo day 1–90 for nMAbs, among patients alive and with day 90 antibody and antigen measures (Sensitivity Analysis). by Elizabeth S. Munroe (21568166)

Subjects:

Long-term anti-nucleocapsid response by baseline patient characteristics. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses by baseline anti-spike neutralizing response assay positivity. by Elizabeth S. Munroe (21568166)

Subjects: